ArticleOncotarget2018
Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer.
Mathilde Guerin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it